RECURSION PHARMACEUTICALS, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-05: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-05 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-05-06 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-06 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-06 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-04-30 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Our Compensation Committee, in consultation with management, Compensia, and legal counsel, has adopted the following practices on equity compensation awards: • Annual awards of equity compensation are made to the executive team, including NEOs, on or about February 1 each year. These awards, through… | |
| 2026-04-30 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Our Compensation Committee, in consultation with management, Compensia, and legal counsel, has adopted the following practices on equity compensation awards: • Annual awards of equity compensation are made to the executive team, including NEOs, on or about February 1 each year. These awards, through… | |
| 2026-04-30 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | Annual awards of equity compensation are made to the executive team, including NEOs, on or about February 1 each year. These awards, through 2025, included stock options and RSUs. In granting the awards, the Compensation Committee determines a dollar value of the awards and the number of shares are … | |
| 2026-04-30 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-30 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Average Summary Compensation Table Total For Non-PEO NEOs (3) ($) Average Compensation Actually Paid to Non-PEO NEOs (2) ($) Value of Initial fixed $100 investment based on: (4) Year Summary Compensation Table Total for PEO (1) ($) Compensation Actually Paid to PEO (2) ($) Total Shareholder Return (… | |
| 2026-04-30 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | Christopher Gibson was our PEO for each year presented. The individuals comprising the non-PEO NEOs for 2025 were Najat Khan and Ben Taylor. The individuals comprising the non-PEO NEOs for 2024 were Ben Taylor, Najat Khan, David Mauro, Tina Marriott, and Michael Secora. The individuals comprising th… | |
| 2026-04-30 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | The amounts shown for “compensation actually paid” have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the PEO or other NEOs. The following table details the applicable adjustments that were made to determine… | |
| 2026-04-30 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | The amounts shown for “compensation actually paid” have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the PEO or other NEOs. The following table details the applicable adjustments that were made to determine… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$8.65M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$2.51M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $3.68M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.24M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.94M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$2.38M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $1.27M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $351.65K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$478.66K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$557.62K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-30 DEF 14A | Additional402v Disclosure | 2025-01-01..2025-12-31 | Total shareholder return (“TSR”) is calculated assuming $100 was invested in the Company’s Class A common stock or the stock represented by the peer group (as applicable) for the period starting April 16, 2021 (the date on which our common stock first began trading on the Nasdaq Global Select Market… | |
| 2026-04-30 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | The peer group used for this table is the Nasdaq Biotechnology Index (the “Index”), which we also utilize for the performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2025. | |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between “compensation actually paid,” as calculated in accordance with Item 402(v) of Regulation S-K (“Compensation Actually Paid”), to our NEOs and the Company’s TSR over the five most recently completed fiscal years. | |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between Compensation Actually Paid to our NEOs and our net income during the five most recently completed fiscal years. While we are required to disclosure our net income (loss) for each covered fiscal year, this is not a metric used in our compensatio… | |
| 2026-04-30 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | The following graph compares the cumulative TSR of Recursion, the Nasdaq Biotechnology Index from our April 16, 2021 closing stock price (the date on which our Class A common stock first began trading on the Nasdaq Global Select Market) through December 31, 2025. This graph assumes $100 was invested… | |
| 2026-02-25 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-25 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-25 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-25 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |